Zgjoib Tag Wart Remover

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the topical treatment of warts. Patients are advised to wash the affected area thoroughly and may soak the wart in warm water for 5 minutes prior to application. After drying the area completely, a sufficient amount of the drug should be applied using a brush to ensure complete coverage of each wart. The application should be allowed to dry, and this procedure may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely. A sufficient amount of the medication should then be applied using a brush, ensuring that each wart is adequately covered. It is important to allow the application to dry completely.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition. The product should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes, as these may lead to adverse reactions or complications. Additionally, individuals with diabetes or poor blood circulation should not use this product, as it may pose significant risks to their health.

Warnings and Precautions

For external use only. This product is flammable; therefore, it must be kept away from fire and flame to prevent any risk of ignition.

In the event of accidental ingestion, it is imperative to seek emergency medical assistance immediately. Healthcare professionals should advise patients to contact the Poison Control Center at 1-800-222-1222 without delay.

Patients are encouraged to remain vigilant and discontinue use if any adverse reactions occur, subsequently contacting their healthcare provider for further guidance.

Side Effects

Patients should be aware that the product is for external use only. It is important to note that the product is flammable; therefore, it should be kept away from fire and flame to prevent any potential hazards.

No additional adverse reactions have been reported in clinical trials or postmarketing experiences.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Zgjoib Tag Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted.

This product is contraindicated for use on irritated skin or any area that is infected or reddened. It should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Caution is advised for pediatric patients with diabetes or poor blood circulation.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients should be advised against the use of this product on irritated skin or any area that is infected or reddened. It is also contraindicated for application on moles, birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membranes. Additionally, the product should not be used by individuals with diabetes or poor blood circulation.

The product is for external use only and is flammable; therefore, it should be kept away from fire and flame. Given these considerations, healthcare professionals should exercise caution when recommending this product to pregnant patients, ensuring that the potential risks are clearly communicated.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate assessment of the patient’s condition is crucial. Recommended actions include:

1. Assessment: Conduct a thorough evaluation of the patient, including vital signs and level of consciousness.

2. Supportive Care: Initiate supportive measures as necessary, which may include airway management, oxygen supplementation, and intravenous fluids.

3. Decontamination: If appropriate and within a reasonable time frame, consider gastrointestinal decontamination methods such as activated charcoal, provided the patient is alert and able to protect their airway.

4. Consultation: Engage with a poison control center or toxicology expert for guidance on specific antidotes or additional management strategies tailored to the substance involved.

It is imperative for healthcare professionals to document all findings and interventions meticulously and to monitor the patient closely for any evolving symptoms or complications.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact the Poison Control Center at 1-800-222-1222 immediately.

Patients should be informed not to use the product on irritated skin or on any area that is infected or reddened. It is also important to caution against using the product on moles, birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membranes. Additionally, patients with diabetes or poor blood circulation should be advised not to use this product.

When using this product, patients should be instructed to avoid contact with the eyes. If the product accidentally gets into the eye, they should flush it with water for 15 minutes. Emphasize that the product is non-edible and should be stored tightly capped at room temperature, away from heat.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at room temperature, ensuring that the storage environment does not exceed excessive heat, defined as 37°C (99°F). Proper handling is essential to maintain the integrity of the product, and care should be taken to avoid conditions that may compromise its quality.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Zgjoib Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)